medigraphic.com

2017, Number 1

<< Back Next >>

Rev Med MD 2017; 8.9 (1)

Results of the 25-gauge chromovitrectomy-membranectomy with triamcinolone by retina surgeons in training

Mendoza-Adam G, Arevalo-Simental D, Cisneros-Gσmez S, Becerra CM, Roig-Melo EA

Language: Spanish
References: 39
Page: 11-17
PDF size: 542.37 Kb.


ABSTRACT

Introduction. The chromovitrectomy is the use of tinture as additive for the visualization of transparent structures during a vitrectomy. Triamcinolone has advantages for being inexpensive, easy to acquire, and not requiring to be removed completely from the retinal tissues. We present a series of epiretinal membrane cases operated by retinal specialists in training using 25-gauge vitrectomy with triamcinolone as adjuvant
Material and Methods. We report 10 cases of primary and secondary epiretinal membrane operated with chromovitrectomy with triamcinolona + epiretinal membrane peeling by medical and surgical retina specialists in training. The variables that were measured were visual acuity, age, gender, follow-up time, etiology, mean Best Corrected Visual Acuity and intraocular pressure pre and post-surgery, the need of use of ocular hypotensive medications, Central Foveal Thickness pre- and post-surgery a month after the treatment, epiretinal membrane recurrence, and any other complication.
Results. The mean age of appearance was 63.6 years old (51-71). The mean duration of follow-up was 9 months (3-12). Both the patients with primary and secondary ERM to diabetic retinopathy had a statistically significant increase in their best corrected visual acuity (p=0.05) and (p=0.01) respectively. The decrease of central foveal thickness was statistically significant for the group of patients with primary epiretinal membrane and it was not so for those with secondary (p=0.03) and (p=0.6). There were no complications trans nor post-operatory.
Discussion. The 25-gauge Chromovitrectomy-Membranectomy assisted with Triamcinolone is a safe and effective technique even when performed by retina surgeons with little experience. The increase on the visual acuity is reached on the primary and secondary Epiretinal Membrane cases. The central foveal thickness may be affected by the previous existence of diabetic retinopathy.


REFERENCES

  1. Rodrigues EB, Meyer CH, Kroll P. 2005. Chromovitrectomy: a new field in vitreoretinal surgery. Graefe's Arch Clin Exp Ophthalmol, 243:291–3.

  2. Ando F, Yasui O, Hirose H, et al. Optic nerve atrophy after vitrectomy with indocyanine green-assisted internal limiting membrane peeling in diffuse diabetic macular edema. Adverse effect of ICGassisted ILM peeling. Graefes Arch Clin Exp Ophthalmol 2004;242:995–999.

  3. Maia M, Haller J, Pieramici DJ, et al. Retinal pigment epithelial abnormalities after internal limiting membrane peeling guided by indocyanine green staining. Retina 2004;24:157–160.

  4. Engelbrecht NE, Freeman J, Sternberg P, et al. Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2002;133:89–94.

  5. Farah ME, Maia M, Rodrigues EB. Dyes in ocular surgery: principles for use in chromovitrectomy. Am J Ophthalmol 2009;148:332–340.

  6. Stanescu-Segall D, Jackson TL. Vital staining with indocyanine green: a review of the clinical and experimental studies relating to safety. Eye 2009;23:504–518.

  7. Beutel J, Dahmen G, Ziegler A, Hoerauf H. Internal limiting membrane peeling with indocyanine green or trypan blue in macular hole surgery: a randomized trial. Arch Ophthalmol 2007;125:326–332.

  8. Penha FM, Maia M, Eid Farah M, et al. Effects of subretinal injections of indocyanine green, trypan blue, and glucose in rabbit eyes. Ophthalmology 2007;114:899–908.

  9. Rodrigues EB, Maia M, Meyer CH, et al. Vital dyes for chromovitrectomy. Curr Opin Ophthalmol. 2007;18:179–187.

  10. Veckeneer M, van Overdam K, Monzer J, et al. 2001. Ocular toxity study of trypan blue injected into the vitreous cavity of rabbit eyes. Graefes Arch Clin Exp Ophthalmol, 239:698–704.

  11. Enaida H, Hisatomi T, Goto Y, et al. Preclinical investigation of internal limiting membrane staining and peeling using intravitreal brilliant blue G. Retina 2006;26:623–630.

  12. Enaida H, Hisatomi T, Hata Y, Ueno A, et al. Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 2006;26:631–636.

  13. Enaida H, Ishibashi T. Brilliant blue in vitreoretinal surgery. Dev Ophthalmol 2008;42:115–125.

  14. Remy M, Thaler S, Schumann RG, et al. An in vivo evaluation of brilliant blue G in animals and humans. Br J Ophthalmol 2008;92:1142–1147.

  15. Schumann RG, Gandorfer A, Priglinger SG, et al. Vital dyes for macular surgery: a comparative electron microscopy study of the internal limiting membrane. Retina 2009;29:669–676.

  16. Floman N, Zor U. 1977. Mechanism of steroid action in ocular infl ammation: inhibition of prostaglandin production. Invest Ophthalmol, 16:69–73.

  17. Lewis GD, Campbell WB, Johnson AR. 1986. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cell. Endocrinology, 199:62–9.

  18. Shah GK, Rosenblatt BJ, Blinder KJ, et al. Triamcinolone assisted internal membrane peeling. Retina 2005;25:972–975.

  19. Shah GK, Rosenblatt BJ, Smith M. Internal limiting membrane peeling using triamcinolone acetonide: histopathologic confirmation. Am J Ophthalmol 2004;138:656–657.

  20. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20:554 –555.

  21. Jin ma, Ke Yao, Zheng Zhang, Xiajing Tang. 25- Gauge Vitrectomy and triamcinolone acetonideassisted internal limiting membrane peeling for chronic cystoid macular edema associated with branch retinal vein occlusion. Retina 28(7):947-956.

  22. Tognetto D, Zenoni S, Sanguinetti G, et al. 2005. Staining of the internal limiting membrane with intravitreal triamcinolone acetonide. Retina, 25:462–7.

  23. Jonas JB, Hayler JK, Panda-Jones S. 2000. Intravitreal injection of crystalline cortisone as a d j u n c t i v e tr e a t m e n t o f p r o l i f e r a t i v e vitreoretinopathy. Br J Ophthalmol, 84:1064–7.

  24. Ueno A, Enaida A, Hata Y, et al. 2007. Long-term clinical outcomes and therapeutic benefi ts of triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy: A case study. Eu J Ophthalmol, 7:392–8.

  25. Furino C, Ferrari TM, Boscia F, et al. 2003. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina, 23:771–6.

  26. Hirata F, Tamura H, Ogura Y. 2005. Visualization of residual perfluorocarbon liquid using intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging, 36:169–72.

  27. Takeuchi M, Katagiri Y, Usui M. 2003. Residual triamcinolone acetonide in the macular hole after vitrectomy. Am J Ophthalmol, 136:1174–6.

  28. Fukukita M, Sasoh M, Matsubara H, et al. 2007. Triamcinolone acetonide remaining on the fovea after successful macular hole closure. Retina, 27:122–3.

  29. Hikichi F, Furukawa Y, Ohtsuka H, et al. 2008. Improvement of visual acuity one-year after vitreous surgery in eyes with residual triamcinolone acetonide at the macular hole. Am J Ophthalmol, 145:267–72

  30. Enaida H, Hata Y, Ueno A, et al. 2003. Possible benefits of triamcinoloneassisted pars plana vitrectomy for retinal diseases. Retina, 23:764–70

  31. Sakamoto T, Miyazaki M, Hisatomi T, et al. 2002. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefe's Arch Clin Exp Ophthalmol, 240:423–9.

  32. Chang C, Chiang S, Chen C, et al. 2006. Clinical outcomes of combined sutureless vitrectomy with triamcinolone stain to manage vitreous loss resulting from posterior capsule rupture during phacoemulsifi cation. J Cataract Refract Surg, 32:2054–9.

  33. Kampougeris G, Chemma R, McPherson R, et al. 2007. Safety of triamcinolone acetonide (TA)- assisted pars plana vitrectomy in macular hole surgery. Eye, 21:591–4.

  34. Kumagai K, Furukawa M, Ogino N, et al. 2007. Long-term outcomes of macular hole surgery with triamcinolone acetonide-assisted internal limiting membrane peeling. Retina, 27:1249–54.

  35. Cherfan GM, Michels RG, de Bustros S, Enger C, Glaser BM. Nuclear sclerotic cataract after vitrectomy for idiopathic epiretinal membranes causing macular pucker. Am J Ophthalmol 1991;111:434–438.

  36. Ting FS, Kwok AK. Treatment of epiretinal membr ane : an upda t e. Hong Kong Me d j 2005;11:496–502.

  37. Ma SS, Barloon S, Maberley AL, Kestle J. Effect of macular edema on surgical visual outcome in eyes with idiopathic epiretinal membrane. Can J Ophthalmol 1996;31:183–186.

  38. Chi-Chun Lai, Nan-Kai Wang, Wei-Chi Wu, Ling Yeung, Yih-Shiou Hwang, Kuan-Jen Chen, Tun-Lu Chen & Lan-Hsin Chuang (2011) The long-term anatomical and visual effect of intravitreal triamcinolone injection during vitrectomy for the treatment of idiopathic macular epiretinal membrane, Cutaneous and Ocular Toxicology, 30:4, 292-297, DOI: 10.3109/15569527.2011.568031

  39. Jonas JB, Kreissig I, Kamppeter B, Degenring RF. Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases. Ophthalmologe 2004;101:113–120.




2020     |     www.medigraphic.com